The World Health Organization claims that “A number

New Post Public Reply Private Reply Replies (2) Message Board
YoggingMarathon
553


The World Health Organization claims that “A number of pathogens are increasingly resistant to existing antibiotics and antifungals,” and that a post-antibiotic era is coming upon us as antibiotic resistance and multidrug-resistant bacteria is becoming a growing concern. Unfortunately, “Resistant strains of bacteria/fungus/yeast are regularly being found for almost every antimicrobial used clinically,” while “…a decline in the approval of new antibiotics has further exacerbated the problem, leading to an antibiotic crisis.”

One promising approach against antibiotic resistance are Anti-Microbial Peptides (AMPs) which are also known as Host Defense Peptides (HDPs) or Cationic Host Defense Peptides CHDPs. AMPs induce little resistance. AMPs cause cell membrane disruption while controlling inflammation and other septic responses to infections. According to researchers, “…many AMPs act on the bacterial invader causing different stresses, until their combined action causes the cell death.”

There are several AMP families, one being “Defensins” in which they are the first line of defense against foreign invasion of the body. These defensins protect the host through their direct or indirect activities on microbes such as bacteria, viruses and fungi. AMPs therefore control infections by killing the foreign bacteria, virus, etc. through its microbicidal properties while also resolving inflammation.


In other words, AMPs exhibit anti-bacterial, anti-inflammatory, anti-fungal, anti-biofilm(build up of bacteria such as plaque), chemoattraction (anti-cancer), and antiviral characteristics.

AMPs can be produced in the following body sites: WBC (Defensins, Cathelicidins); kidney; small intestine; eye; skin (soap can wash AMPs off causing E. Coli to grow!); tongue; airways; colon; reproductive tract. AMPs can also be found in lymphocytes.


Research also indicates that AMPs have “…the potential to become a preventative strategy against viral infections, especially during emerging pandemics…but their application is still at the preliminary stages.”



Brilacidin is a synthetic AMP defensin-mimetic drug. Synthetic defensin-mimetic drugs like Brilacidin are less toxic and cheaper to manufacture than natural AMPs. Brilacidin is also 100 times more powerful than natural AMPs and 1000 times more selective than natural AMPs as its potent against the foreign host target while leaving host cells unaffected.

Brilacidin functions as an anti-microbial that causes rapid bacterial cell death. “This rapid killing ability makes antibiotic resistance less likely.”


Brilacidin’s defensin-based therapeutic has been through more clinical testing than any other defensin-based therapeutic drug. Through clinical testing, Brilacidin has already demonstrated broad and robust anti-bacterial, anti-inflammatory and immunomodulatory properties in multiple FDA clinical trials (treatment of ABSSSI, IBD, OM and soon a topical agent for Atopic Dermatitis and Acne). In addition, Brilacidin does not cause systemic buildup in trials to date which means that it clears the body fast. Research also indicates that “Brilacidin has also shown that it does not interfere with other medications…does not cause any types of major side issues with patients in regards to causing pain or becoming uncomfortable.”


Immunomodulators, like Brilacidin, have “…antimicrobial peptide rhesus ?-defensin 1, which have shown to have an anti-SARS-CoV effect (The virus responsible for COVID-19).” In pre-clinical tests, Brilacidin has shown to “disrupt viral replication” while “enhancing the protective role of natural surfactants in the lung”. Currently, virologists are not only studying AMPs antiviral properties but their “…regulation of inflammation and chemo-attraction.” Defensin-based therapeutics (such as Brilacidin) have potential in treating the following cancers: esophageal cancer, lung cancer, bladder cancer, cervical cancer, oral cancer, skin carcinoma, tumor-induced immune evasion, renal cancer, prostate cancer, skin cancer and colorectal cancer.


Thus far, U.S. Government’s Biomedical Advanced Research and Development Authority (BARDA), the National Institute of Allergy and Infectious Diseases (NIAID), one of U.S.’s 12 Regional Biocontainment Labs (RBLs) and a major U.S. university with one of the world’s leading coronavirus experts are all planning to evaluate Brilacidin for viruses. Brilacidin will be researched for its anti-viral properties that could possibly control and/or treat the COVID-19 and other RNA viruses (I.e. influenza, asthma, RSV, Rhinovirus, Adenovirus, HPV-16, HSV, HIV, Vaccinia Virus, Zika Virus, Kaposi’s sarcoma-associated herpesvirus).

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 718

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 97

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 302

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 158

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 410

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 262

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 203

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 216

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 385

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading

Top 5 Most Recently Viewed Articles

Blend's AWS Financial Services Competency Enhances Innovations

Updated Category News Views 152

Blend Takes a Major Stride with AWS Financial Services Competency Exciting news emerges from Blend as the company secures a crucial recognition in the cloud technology arena. They've recently achieved the prestigious AWS Financial Services Competency badge, a testament to their outstanding expertise and remarkable track record in delivering innovative, secure, and...

Continue Reading
The Upcoming Surge of Last Mile Delivery Market Growth

Updated Category News Views 289

Overview of the Last Mile Delivery Market Growth The Last Mile Delivery market is poised for significant growth in the coming years, projected to rise by USD 51.1 billion from 2025 to 2029. This increase is primarily driven by the expanding global e-commerce sector and the integration of advanced technologies, including AI, which are transforming logistical operations....

Continue Reading
Tide Rock Expands Its Precision Machining Horizons Through Acquisitions

Updated Category News Views 326

Tide Rock Expands Its Precision Machining Horizons Tide Rock has taken a significant leap forward in the field of advanced precision machining through its recent acquisitions. By acquiring Precision Waterjet & Laser, now known as Precision Advanced Machining, located in Anaheim, California, and Made in America Manufacturing based in Buda, Texas, Tide Rock is enhancing its...

Continue Reading
Novavax Revises Projections, Anticipates Robust Nuvaxovid Demand

Updated Category News Views 149

Novavax Reports Strong Second Quarter Results Recently, Novavax Inc. reported impressive sales of $239.24 million for the second quarter of 2025, marking a significant shift from $415 million during the same period in the previous year. This figure exceeded the Wall Street consensus expectations, which estimated sales at $156.29 million. Such growth highlights Novavax's...

Continue Reading
Insights into Novartis' Cosentyx and GCAptAIN Study Findings

Updated Category News Views 219

Novartis' Groundbreaking Updates on Cosentyx in GCAptAIN Study Novartis has recently provided significant updates regarding the Phase III GCAptAIN study, focusing on the efficacy of Cosentyx (secukinumab) for patients suffering from giant cell arteritis (GCA). This condition, predominantly affecting older adults, poses a risk of severe complications if not managed...

Continue Reading